Selective inhibitors of the kinase and/or RNase domains of human IRE1 are under development for the purpose of creating toxic levels of unfolded proteins in human tumor cells, particularly when used in combination with drugs that exacerbate ER stress (18, 19, 48, 49). This evidence concerns the gene ERN1 and neoplasm.